Jeffrey Larnard

Orthopedic implant infections—including prosthetic joint infections (PJI), fracture-related infections (FRI), and spinal implant infections (SII)—represent a spectrum of biofilm-associated infections that are associated with substantial morbidity, prolonged antimicrobial therapy, and frequent need for surgical intervention. Rifampin is often incorporated into antimicrobial treatment regimens for orthopedic implant infections due to its potent biofilm-penetrating properties and has been most studied in the treatment of staphylococcal PJIs, though the majority of data is observational. Its use is frequently complicated by adverse effects and significant drug–drug interactions, and the role of rifampin beyond staphylococcal PJIs managed with implant retention or one-stage exchange remains controversial. In this review, we critically evaluate the evidence for use of rifampin in PJI, with additional consideration of its role in FRIs, SIIs, and PJIs caused by staphylococcal and other Gram-positive organisms. Using illustrative cases, we provide a practical framework for navigating common clinical scenarios and challenges involving the use of rifampin in orthopedic implant infections.

First described in the United States, outpatient parenteral antibiotic therapy (OPAT) has become an indispensable part of treating serious infections. The proportion of infectious disease (ID) physicians utilizing a formal OPAT program has increased in recent years, but remains a minority. In addition, many ID physicians have indicated that OPAT programs have inadequate financial and administrative support. Given the medical complexity of patients receiving OPAT, as well as the challenges of communicating with OPAT providers across health care facilities and systems, OPAT programs ideally should involve a multidisciplinary team. The majority of patients in the United States receive OPAT either at home with assistance from home infusion companies and visiting nurses or at a skilled nursing facility (SNF), though the latter has been associated with lower rates of patient satisfaction. Current and future opportunities and challenges for OPAT programs include providing OPAT services for people who inject drugs (PWID) and incorporating the increasing use of oral antibiotics for infections historically treated with parenteral therapy. In this review, we will discuss the current practice patterns and patient experiences with OPAT in the United States, as well as identify future challenges and opportunities for OPAT programs.

Background: Little is known about antimicrobial prescribing when patient care is transitioned to comfort measures only (CMO). We used a multidisciplinary survey and retrospective cohort study to gain insight into antimicrobial prescribing in this population at an academic medical center to inform future antimicrobial stewardship interventions. Methods: A survey focusing on antimicrobial prescribing during the transition to CMO was electronically distributed to providers in medical subspecialities and responses were compared across specialties. A retrospective chart review was performed of patients admitted to an academic medical center in 2020 who were on antimicrobials in the 48 hours prior to CMO. We investigated the percentage of patients who remained on antimicrobials after the transition to CMO and rationale for continuing antimicrobials. Results: We received 113 survey responses (35% response rate). Forty-one percent of respondents indicated that they “sometimes” or “often” continued antimicrobials during the transition to CMO. Patient/family preference and symptom palliation were the most common factors cited by respondents when deciding whether to continue antimicrobials in this population. Of the 546 patient charts reviewed, 140 (26%) patients were alive 48 hours after CMO order, and 19 (14%) of those patients remained on antimicrobials. Five of 19 (26%) patients had documentation that antimicrobials were continued due to patient/family preference and 5 of 19 (26%) patients had documentation that antimicrobials were continued for palliation of symptoms. Conclusions: Patient/family preference and symptom palliation are important factors in prescribing antimicrobials when patient care is transitioned to CMO. More evidence is needed regarding palliative benefits of antibiotics to inform provider discussions of benefits and harms of antimicrobial use in this setting.